PRESS RELEASE published on 01/20/2026 at 18:00, 9 months 22 days ago THX Pharma publie son agenda financier 2026 THX Pharma publie son agenda financier 2026, incluant les dates de communication financière et informations sur ses médicaments innovants. Retrouvez plus d'informations sur http://www.theranexus.com Communication Financière Agenda Financier Médicaments Neurologiques Rares THX Pharma
BRIEF published on 01/08/2026 at 18:05, 10 months 3 days ago Publication of the letter to shareholders by Theranexus Shareholders Neuroscience Rare Diseases Theranexus Drugs
BRIEF published on 01/08/2026 at 18:05, 10 months 3 days ago Publication de la lettre aux actionnaires par Theranexus Actionnaires Médicaments Maladies Rares Theranexus Neurosciences
BRIEF published on 01/08/2026 at 18:05, 10 months 3 days ago THX Pharma Releases Shareholder Letter Drug Development Biopharmaceutical Shareholder Communication Neurological Diseases THX Pharma
BRIEF published on 01/08/2026 at 18:05, 10 months 3 days ago THX Pharma publie une lettre aux actionnaires Biopharmaceutique Communication Aux Actionnaires Développement De Médicaments Maladies Neurologiques THX Pharma
PRESS RELEASE published on 01/08/2026 at 18:00, 10 months 3 days ago THX Pharma annonce la publication de sa lettre aux actionnaires Theranexus annonce la publication de sa lettre aux actionnaires. THX Pharma se spécialise dans le traitement des maladies neurologiques rares. Plus d'infos sur leur site Actionnaires Newsletter Theranexus Maladies Neurologiques Rares THX Pharma
PRESS RELEASE published on 01/08/2026 at 18:00, 10 months 3 days ago THX Pharma announces the publication of its letter to shareholders THX Pharma (Theranexus) announces the publication of its letter to shareholders, highlighting treatments for rare neurological diseases and upcoming drug commercialization. Forward-looking statements included Forward-looking Statements Theranexus Neurological Diseases THX Pharma Drug Commercialization
BRIEF published on 01/07/2026 at 08:05, 10 months 4 days ago THX Pharma appoints Julien Veys as Deputy General Manager Business Strategy Appointment THX Pharma Julien Veys Neurological Medications
BRIEF published on 01/07/2026 at 08:05, 10 months 4 days ago THX Pharma Names Julien Veys as Deputy CEO Rare Neurological Diseases THX Pharma Julien Veys Appointment Theranexus Strategy Pharmaceutical Commercialization
BRIEF published on 01/07/2026 at 08:05, 10 months 4 days ago THX Pharma nomme Julien Veys au poste de Directeur général adjoint Nomination Stratégie Commerciale THX Pharma Julien Veys Médicaments Neurologiques
Published on 11/11/2026 at 23:30, 22 minutes ago Faraday Copper Reports Third Quarter 2026 Financial Results and Announces Changes to the Board of Directors
Published on 11/11/2026 at 23:05, 47 minutes ago Vox Royalty Reports Q3 2026 Results and Declares Quarterly Dividend
Published on 11/11/2026 at 23:00, 52 minutes ago CCL Industries Announces Appointment of New Director
Published on 11/11/2026 at 22:30, 1 hour 22 minutes ago 55 North Gold Qualifies for Trading on the OTCQB Venture Market and Launches New Corporate Website
Published on 11/11/2026 at 19:31, 4 hours 21 minutes ago Lion Copper Corp. Completes S-K 1300 Technical Report Summary for Bear Copper Deposit
Published on 11/11/2026 at 19:29, 4 hours 23 minutes ago EQS-Adhoc: Allianz SE: Allianz delivers record nine-month result of 14.1 billion euros and raises 2026 outlook
Published on 11/11/2026 at 18:41, 5 hours 11 minutes ago AUSTRIACARD HOLDINGS AG: 9M 2026 Financial Results
Published on 11/10/2026 at 18:00, 1 day 5 hours ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 1 day 6 hours ago Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:35, 1 day 6 hours ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 1 day 6 hours ago CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.
